AUS
NZ
UK
CA
USA
IND
Highlights
- Hemogenyx develops a novel method to deliver Chimeric Bait Receptors (CBR) to immune cells using lentiviral vectors.
- The breakthrough enhances macrophage and monocyte efficacy, key components of the immune system.
- This advancement accelerates the progress of CBR-based product candidates toward clinical development.
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF), a clinical-stage biopharmaceutical company, has announced a major breakthrough in its efforts to enhance the delivery of Chimeric Bait Receptors (CBR) to immune cells. This development marks a critical step in advancing the company’s innovative approach to immunotherapy.
Focus on Immune System Enhancement
Hemogenyx’s novel CBR technology targets the body’s innate immune cells, specifically macrophages and monocytes. These white blood cells act as the first responders in defending the body against infections and eliminating damaged or diseased cells. By enhancing their performance, Hemogenyx aims to improve the immune system’s ability to combat harmful elements more effectively.
Lentiviral Vectors: A Revolutionary Delivery Mechanism
Central to this breakthrough is the use of lentiviral vectors—specially engineered viruses designed to introduce new genetic material into cells. This technology allows for efficient and long-lasting expression of CBR within immune cells, enabling them to target harmful elements with greater precision and efficacy.
By leveraging lentiviral vectors, Hemogenyx has overcome key challenges associated with the delivery of genetic material to myeloid immune cells. This achievement is expected to streamline the development of CBR-based therapies and accelerate their transition to Investigational New Drug (IND)-enabling studies.
Significance of the Breakthrough
This advancement not only underscores the potential of Hemogenyx’s CBR technology but also paves the way for the development of transformative therapies targeting a range of diseases. By enhancing the functionality of macrophages and monocytes, Hemogenyx is pushing the boundaries of immunotherapy and broadening the scope of potential applications for its platform.
CEO’s Perspective
Dr. Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, highlighted the importance of the breakthrough:
“Overcoming the challenges of efficiently delivering CBRs to myeloid immune cells has been a key focus for our team, and this breakthrough underscores their dedication and ingenuity. We remain committed to leveraging this technology to bring transformative therapies to the clinic and, ultimately, to patients in need.”
Dr. Sandler added that the company’s next steps involve allocating resources to advance CBR-based therapies into clinical development.
Looking Ahead
With this breakthrough, Hemogenyx Pharmaceuticals is poised to make significant strides in the development of immunotherapies. The company’s innovative approach to leveraging innate immune cells positions it as a leader in the field, with the potential to deliver impactful treatments for various diseases.
As Hemogenyx continues to refine its platform and advance its therapies, the focus remains on translating these scientific achievements into clinical success, offering hope for patients in need of cutting-edge medical solutions.
